--- title: FELDAN ANNOUNCES THE APPOINTMENT OF ERIC CARTER, PH.D., M.D., TO ITS BOARD OF DIRECTORS description: Feldan Therapeutics Board of Directors Eric Carter --- [![Feldan therapeutics](https://www.feldan.com/hs-fs/hubfs/FELDAN-lg-couleur.png?width=2379&height=1537&name=FELDAN-lg-couleur.png "Feldan therapeutics")](https://www.feldan.com/?hsLang=en) [![Contact us](https://no-cache.hubspot.com/cta/default/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6.png)](https://cta-redirect.hubspot.com/cta/redirect/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6) ** [** ](https://www.linkedin.com/company/feldantherapeutics/) [** ](https://www.facebook.com/feldantherapeutics) ** ** [![FELDAN-lg-couleur250](https://www.feldan.com/hs-fs/hubfs/FELDAN-lg-couleur250.png?width=200&height=81&name=FELDAN-lg-couleur250.png "FELDAN-lg-couleur250")](https://www.feldan.com/?hsLang=en) [![Contact us](https://no-cache.hubspot.com/cta/default/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6.png)](https://cta-redirect.hubspot.com/cta/redirect/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6) ** [** ](https://www.linkedin.com/company/feldantherapeutics/) [** ](https://www.facebook.com/feldantherapeutics) ** ** Search **Menu** ** ** [![Contact us](https://no-cache.hubspot.com/cta/default/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6.png)](https://cta-redirect.hubspot.com/cta/redirect/6481368/a79f9fa2-131e-425f-8bcb-bc74a0bd68c6) # FELDAN ANNOUNCES THE APPOINTMENT OF ERIC CARTER, PH.D., M.D., TO ITS BOARD OF DIRECTORS by [Feldan](https://www.feldan.com/news/author/feldan) on Jan 22,2025 Quebec City, Canada, January 22, 2025 — Feldan Therapeutics (“Feldan”), a clinical-stage pharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, is pleased to announce the appointment of Dr. Eric Carter to its Board of Directors. ‘’Feldan holds the promise of transformative treatment options that can meaningfully improve the lives of patients. I am very pleased to join my fellow Board members in advancing the development of important new therapies for patients,’’ said Dr. Carter. Dr. Carter brings more than three decades of distinguished experience in the pharmaceutical industry, having held prominent roles in clinical and non-clinical development. As the former Chief Medical Officer and Global Head of Development at Allergan, Inc., he led groundbreaking initiatives that set new standards in the field. Beyond Allergan, Dr. Carter has held influential leadership positions at renowned organizations such as Alder Biopharmaceuticals, King Pharmaceuticals, GSK, and Pharmacia. He currently serves as Chief Medical Officer of IACTA Pharmaceuticals and also lends his expertise as a board member and chair of the Scientific Advisory Committees of Aeon Biopharma and Visgenx, Inc. With a Ph.D. from the University of Cambridge and an M.D. from the University of Miami, Dr. Carter’s academic foundation further highlights his lifelong commitment to advancing medical science and innovation. “We are delighted to welcome Eric to our Board,” said François-Thomas Michaud, co-founder and Chief Executive Officer of Feldan. “As we advance the ongoing Phase 1/2a clinical trial of FLD-103, Eric’s deep clinical expertise and background as a practicing physician bring an invaluable perspective to our team and enrich the collective strengths of our current Board. We are confident that Dr. Carter’s contributions will be significant in shaping our efforts to develop transformative therapies and bring value to Feldan.” **Feldan’s Board of Directors: **- David Mazzo, Chairman of the Board – President and Chief Executive Officer, Lisata Therapeutics - Nathalie Chauret – Consultant to the pharmaceutical industry - Paul Truex – Chairman of the Board and Chief Executive Officer, Thryv Therapeutics - Elisabeth Sandoval Little – Consultant to the pharmaceutical industry - Eric Carter – Chief Medical Officer, IACTA Pharmaceuticals - Jamie Stiff – Managing Director, Genesys Capital   - François-Thomas Michaud – Co-founder and Chief Executive Officer, Feldan  **About Feldan: **Located in Quebec City, Canada, Feldan is a clinical-stage pharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan is behind the design of a proprietary peptide-based technology, the Feldan Shuttle, which enables safe and efficient delivery of antisense oligonucleotides (ASO) inside cells, unlocking the potential for a new generation of therapies. Feldan’s pipeline currently focuses on diseases affecting the lungs and skin.   Feldan is currently advancing its clinical-stage intralesional FLD-103, a promising non-surgical treatment for basal cell carcinomas (BCC). Phase 1/2a study will assess the safety, tolerability, and preliminary efficacy of FLD-103. Basal cell carcinoma is the most common skin cancer and the most frequent form of all cancers, with more than 3.6 million BCCs diagnosed in the US and Canada each year. Patients affected by BCC commonly develop tumors in sun-exposed areas such as the face, neck and scalp and mostly rely on surgical treatment. Surgery is an effective yet invasive and disfiguring procedure that leaves patients to deal with scarring and, in some instances, a long recovery time. FLD-103 will offer a non-surgical treatment, with the potential of improved aesthetics and enhanced patient quality of life compared to surgery. Feldan is also working on advancing its pulmonary delivery program towards clinical development and further leveraging its intracellular delivery technology to bring life-changing therapeutics to patients.  For more information: [www.feldan.com](https://www.feldan.com/?hsLang=en)  **Contact:**  Stéphanie Levesque  Director – Corporate Governance & Communications  418.872.7277 I [slevesque@feldan.com](mailto:slevesque@feldan.com)  - [Recent](https://www.feldan.com/news/feldan-announces-the-appointment-of-eric-carter-ph.d.-m.d.-to-its-board-of-directors#recent) - [Archive](https://www.feldan.com/news/feldan-announces-the-appointment-of-eric-carter-ph.d.-m.d.-to-its-board-of-directors#archive) - [January 2018 (2)](https://www.feldan.com/news/archive/2018/01) - [March 2018 (2)](https://www.feldan.com/news/archive/2018/03) - [April 2018 (2)](https://www.feldan.com/news/archive/2018/04) - [May 2018 (2)](https://www.feldan.com/news/archive/2018/05) - [June 2018 (2)](https://www.feldan.com/news/archive/2018/06) - [November 2018 (2)](https://www.feldan.com/news/archive/2018/11) - [June 2019 (2)](https://www.feldan.com/news/archive/2019/06) - [April 2021 (2)](https://www.feldan.com/news/archive/2021/04) - [June 2023 (2)](https://www.feldan.com/news/archive/2023/06) - [February 2024 (2)](https://www.feldan.com/news/archive/2024/02) - [March 2026 (2)](https://www.feldan.com/news/archive/2026/03) - [September 2016 (1)](https://www.feldan.com/news/archive/2016/09) - [April 2017 (1)](https://www.feldan.com/news/archive/2017/04) - [August 2017 (1)](https://www.feldan.com/news/archive/2017/08) - [September 2018 (1)](https://www.feldan.com/news/archive/2018/09) - [October 2018 (1)](https://www.feldan.com/news/archive/2018/10) - [December 2018 (1)](https://www.feldan.com/news/archive/2018/12) - [February 2019 (1)](https://www.feldan.com/news/archive/2019/02) - [October 2019 (1)](https://www.feldan.com/news/archive/2019/10) - [June 2020 (1)](https://www.feldan.com/news/archive/2020/06) - [January 2021 (1)](https://www.feldan.com/news/archive/2021/01) - [February 2021 (1)](https://www.feldan.com/news/archive/2021/02) - [January 2022 (1)](https://www.feldan.com/news/archive/2022/01) - [March 2023 (1)](https://www.feldan.com/news/archive/2023/03) - [April 2023 (1)](https://www.feldan.com/news/archive/2023/04) - [August 2023 (1)](https://www.feldan.com/news/archive/2023/08) - [September 2023 (1)](https://www.feldan.com/news/archive/2023/09) - [October 2023 (1)](https://www.feldan.com/news/archive/2023/10) - [December 2023 (1)](https://www.feldan.com/news/archive/2023/12) - [September 2024 (1)](https://www.feldan.com/news/archive/2024/09) - [October 2024 (1)](https://www.feldan.com/news/archive/2024/10) - [January 2025 (1)](https://www.feldan.com/news/archive/2025/01) - [February 2025 (1)](https://www.feldan.com/news/archive/2025/02) - [April 2025 (1)](https://www.feldan.com/news/archive/2025/04) - [June 2025 (1)](https://www.feldan.com/news/archive/2025/06) - [September 2025 (1)](https://www.feldan.com/news/archive/2025/09) - [January 2026 (1)](https://www.feldan.com/news/archive/2026/01) [More...](https://www.feldan.com/news/feldan-announces-the-appointment-of-eric-carter-ph.d.-m.d.-to-its-board-of-directors#) ![FELDAN-lg-blanc-1](https://www.feldan.com/hs-fs/hubfs/FELDAN-lg-blanc-1.png?width=296&name=FELDAN-lg-blanc-1.png) ## Address 2666, Boul. du Parc Technologique, Suite 290 Quebec, Qc, Canada, G1P 4S6 Phone: [1-418-872-7277](tel:1-418-872-7277) Email: [info@feldan.com](mailto:info@feldan.com) [** ](https://www.linkedin.com/company/feldantherapeutics/) [** ](https://www.facebook.com/feldantherapeutics) Copyright © Feldan Therapeutics, 2024. All Rights Reserved.